Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 11/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 11/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 3/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.54 |
| ▸ | PDE2A | O00408 | 1/20 | 0.54 |
| ▸ | PDE1A | P54750 | 1/20 | 0.54 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21970679 | 1.00 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL16156987 | 0.88 | PDE3B (0.79) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL16157210 | 0.87 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL16156966 | 0.87 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL16156997 | 0.87 | PDE3B (1.00) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL17446951 | 0.84 | PDE3B (0.73) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL10353457 | 0.83 | PDE3B (0.71) | PDE3BPDE3AMAPTPDE4APDE4B | |
| SCHEMBL10667501 | 0.81 | PDE3B (0.74) | PDE3BPDE3AKDM4EALDH1A1MAPT | |
| SCHEMBL16157200 | 0.78 | PDE3B (0.73) | PDE3BPDE3APDE4APDE4BPDE4C | |
| SCHEMBL31473121 | 0.78 | PDE3B (0.63) | PDE3BPDE3AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411037-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | Bayer Pharma AG (DE) | 2021-10-20 | — | — | EP | disclosed |
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-05 | — | — | US | disclosed |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-06 | — | — | US | disclosed |
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| WO-2017134231-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | WO | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236504-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CANCER PATIENT STRATIFICATION AND CANCER TREATMENT | CREB1, CREBBP, SLFN12 | PDE3B 11/4885PDE3A 7/4885KDM4E 2202/4885 |
| US-10966986-B2 | Compounds, compositions and methods for cancer patient stratification and cancer treatment | SLFN12, CREB1, CREBBP | PDE3B 10/4885PDE3A 6/4885KDM4E 2614/4885 |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3B 2667/4885PDE3A 2661/4885KDM4E 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.